Literature DB >> 12751903

Osteogenic potential of rat spleen stromal cells.

Anna R Derubeis1, Maddalena Mastrogiacomo, Ranieri Cancedda, Rodolfo Quarto.   

Abstract

Evidence is mounting that an increasing number of cell populations in the adult organism already committed and/or differentiated retain the ability to reprogram themselves and give rise to a different phenotype. Bone marrow stromal cells have long been recognized as early progenitor cells for osteoblasts, chondrocytes, hematopoietic-supportive fibroblasts and adipocytes. Recent reports though have demonstrated a potential of cell populations outside the bone marrow environment to sustain bone formation under specific circumstances. The formation of bone nodules in the spleen of IL-5 transgenic mice has been recently reported (Macias et al. (2001): J. Clin. Invest. 107, 949 - 959). We thus postulated that a cell population exists in the spleen that under particular microenvironmental conditions is able to reprogram itself and pursue a fate other than the tissue-specific one. Therefore we isolated and expanded in vitro spleen-derived stromal cells. After expansion, these cells were challenged with culture conditions designed to induce osteogenic differentiation. We hypothesized that the combination of a proliferating factor (fibroblast growth factor 2) and a differentiating hormone (dexamethasone) would allow us to induce spleen-derived stromal cells to proliferate and at the same time to express osteoblast-specific genes. Thus, spleen-derived stromal cells were isolated from rat spleen and expanded in the presence of fibroblast growth factor 2 and dexamethasone. Once primary cultures reached confluence they were either switched to an osteo-inductive medium or implanted in immunodeficient mice. Although no bone formation was observed in in vivo experiments, in vitro spleen-derived stromal cells were able to deposit a mineralized matrix. Gene expression, as revealed by RT-PCR analysis, evidenced that the deposition of a mineralized matrix was concomitant with the expression of CBFA1 and osteocalcin, along with alkaline phosphatase and bone sialoprotein. Our data suggest that rat spleen-derived stromal cells can undergo osteogenic differentiation in a permissive microenvironment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12751903     DOI: 10.1078/0171-9335-00300

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  6 in total

1.  Creation of new bone by the percutaneous injection of human bone marrow stromal cell and HA/TCP suspensions.

Authors:  Mahesh H Mankani; Sergei A Kuznetsov; Grayson W Marshall; Pamela Gehron Robey
Journal:  Tissue Eng Part A       Date:  2008-12       Impact factor: 3.845

Review 2.  Liver-spleen axis: intersection between immunity, infections and metabolism.

Authors:  Giovanni Tarantino; Antonella Scalera; Carmine Finelli
Journal:  World J Gastroenterol       Date:  2013-06-21       Impact factor: 5.742

3.  In vivo bone formation by progeny of human embryonic stem cells.

Authors:  Sergei A Kuznetsov; Natasha Cherman; Pamela Gehron Robey
Journal:  Stem Cells Dev       Date:  2010-09-14       Impact factor: 3.272

4.  In vivo formation of bone and haematopoietic territories by transplanted human bone marrow stromal cells generated in medium with and without osteogenic supplements.

Authors:  Sergei A Kuznetsov; Mahesh H Mankani; Pamela Gehron Robey
Journal:  J Tissue Eng Regen Med       Date:  2011-11-03       Impact factor: 3.963

5.  Removal of the spleen in mice alters the cytokine expression profile of the marrow micro-environment and increases bone formation.

Authors:  Fabrizio Martelli; Maria Verrucci; Giovanni Migliaccio; Maria Zingariello; Rosa Alba Rana; Alessandro Maria Vannucchi; Anna Rita Migliaccio
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

6.  Existence of Neural Stem Cells in Mouse Spleen.

Authors:  Koichi Tomita; Hiroshi Ishikawa
Journal:  ScientificWorldJournal       Date:  2019-01-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.